MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Propranolol therapy for tardive dyskinesia: A retrospective examination

S.A. Factor, K.A. Armstrong, J.M. Hatcher-Martin (Atlanta, GA, USA)

Meeting: 2016 International Congress

Abstract Number: 902

Keywords: Propranolol, Tardive dyskinesia(TD)

Session Information

Date: Tuesday, June 21, 2016

Session Title: Drug-induced movement disorders

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To examine the tolerability and effectiveness of propranolol in treating tardive dyskinesia (TD).

Background: TD is a disabling, often irreversible, movement disorder that results from chronic therapy with dopamine receptor blocking drugs. There are currently no approved treatments. Propranolol, a β-adrenergic blocker, was FDA-approved in 1967 for cardiovascular disease and is used in several other disorders. In the 1980s, several case reports, series, and one small blinded trial demonstrated that over 60% of patients had notable response with low doses. In 2013, we reported a small case series that demonstrated similar response. Propranolol has been a standard early line therapy for TD in the Emory movement disorder clinic. The purpose of this study was to analyze the effect in a larger cohort.

Methods: Database search of Emory movement disorder clinic for TD patients treated with propranolol followed by record review.

Results: 48 patients were analyzed, mean age 63 years, duration of neuroleptic therapy before TD 78 months and duration of TD at the time propranolol was initiated 17 months. Severity of TD was based on a 0-3 scale (0=none, 1=mild, 2=moderate, 3 =severe). Mean severity 2.2. Response was based on a 0-3 scale (0=no response, 1= mild, 2=moderate, 3= significant or complete response). 62% responded to propranolol (mean response score 1.3) and 77% of those had a moderate to significant response. Mean daily dose was 69 mg and duration of therapy 14 months. Three stopped the medication due to adverse effects: two with hypotension and one with nightmares. Analysis of variance was used to find predictors of response, dose and duration of propranolol showed trends.

Conclusions: Propranolol, at low doses, appears to be well tolerated and effective in treating TD for a majority of patients at a magnitude similar to that reported 30 years ago. A prospective randomized trial is warranted.

To cite this abstract in AMA style:

S.A. Factor, K.A. Armstrong, J.M. Hatcher-Martin. Propranolol therapy for tardive dyskinesia: A retrospective examination [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/propranolol-therapy-for-tardive-dyskinesia-a-retrospective-examination/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/propranolol-therapy-for-tardive-dyskinesia-a-retrospective-examination/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley